PDCD1 and non-small cell lung carcinoma: Additionally, the potential of 18F-FDG-PET to predict the major pathological response (MPR) upon treatment with neoadjuvant anti-PD-1 antibody (sintilimab) was examined in 36 patients with resectable NSCLC [38].